Typical injection site hypertrophy is several inches or centimeters across, smoothly rounded, and somewhat firmer than ordinary subcutaneous fat. There may be some scar tissue as well, but the major component is adipose tissue, as insulin exerts a hypertrophic effect on adipose cells. To avoid lipohypertrophy, persons with diabetes mellitus who inject insulin daily for an extended period of time are advised to rotate their injections among several areas (usually upper, outer arms, outer thighs, abdomen below and around the umbilicus, and the upper parts of the buttocks). Rotation charts are often provided as part of diabetes education to help prevent lipohypertrophy.
Lipohypertrophy usually will gradually disappear over months if injections in the area are avoided.
It is a common misconception that the lump is largely scar tissue, as injection site hypertrophy is much rarer and milder with injections of other hormones and medications which lack the specific ability of insulin to stimulate adipose hypertrophy.
In a sense, the "opposite" of injection site lipohypertrophy is injection site lipoatrophy, in which the subcutaneous fat around an injected area "melts away" over a few weeks or months, leaving unsightly, well-demarcated depressions in the skin. The mechanism of this local lipoatrophy is not understood and may involve autoimmunity or local inflammation.
Vardar B, Kizilci S (August 2007). "Incidence of lipohypertrophy in diabetic patients and a study of influencing factors". Diabetes Research and Clinical Practice. 77 (2): 231–6. doi:10.1016/j.diabres.2006.12.023. PMID 17303282.
Hauner H, Stockamp B, Haastert B (15 July 2009). "Prevalence of lipohypertrophy in insulin-treated diabetic patients and predisposing factors". Experimental and Clinical Endocrinology & Diabetes. 104 (2): 106–10. doi:10.1055/s-0029-1211431. PMID 8740933.
Blanco M, Hernández MT, Strauss KW, Amaya M (October 2013). "Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes". Diabetes & Metabolism. 39 (5): 445–53. doi:10.1016/j.diabet.2013.05.006. PMID 23886784.
December 15, 2023
lipohypertrophy, lump, under, skin, caused, accumulation, extra, site, many, subcutaneous, injections, insulin, unsightly, mildly, painful, change, timing, completeness, insulin, action, common, minor, chronic, complication, diabetes, mellitus, typical, inject. Lipohypertrophy 1 is a lump under the skin caused by accumulation of extra fat at the site of many subcutaneous injections of insulin It may be unsightly mildly painful and may change the timing or completeness of insulin action It is a common minor chronic complication of diabetes mellitus Typical injection site hypertrophy is several inches or centimeters across smoothly rounded and somewhat firmer than ordinary subcutaneous fat There may be some scar tissue as well but the major component is adipose tissue as insulin exerts a hypertrophic effect on adipose cells To avoid lipohypertrophy persons with diabetes mellitus who inject insulin daily for an extended period of time are advised to rotate their injections among several areas usually upper outer arms outer thighs abdomen below and around the umbilicus and the upper parts of the buttocks Rotation charts are often provided as part of diabetes education to help prevent lipohypertrophy Lipohypertrophy usually will gradually disappear over months if injections in the area are avoided It is a common misconception that the lump is largely scar tissue as injection site hypertrophy is much rarer and milder with injections of other hormones and medications which lack the specific ability of insulin to stimulate adipose hypertrophy In a sense the opposite of injection site lipohypertrophy is injection site lipoatrophy in which the subcutaneous fat around an injected area melts away over a few weeks or months leaving unsightly well demarcated depressions in the skin The mechanism of this local lipoatrophy is not understood and may involve autoimmunity or local inflammation See also editInvolutional lipoatrophy List of cutaneous conditionsReferences edit Rapini RP Bolognia JL Jorizzo JL 2007 Dermatology 2 Volume Set St Louis Mosby ISBN 978 1 4160 2999 1 Further reading editYoung RJ Hannan WJ Frier BM Steel JM Duncan LJ 1 September 1984 Diabetic lipohypertrophy delays insulin absorption Diabetes Care 7 5 479 80 doi 10 2337 diacare 7 5 479 PMID 6389062 S2CID 8148898 Vardar B Kizilci S August 2007 Incidence of lipohypertrophy in diabetic patients and a study of influencing factors Diabetes Research and Clinical Practice 77 2 231 6 doi 10 1016 j diabres 2006 12 023 PMID 17303282 Hauner H Stockamp B Haastert B 15 July 2009 Prevalence of lipohypertrophy in insulin treated diabetic patients and predisposing factors Experimental and Clinical Endocrinology amp Diabetes 104 2 106 10 doi 10 1055 s 0029 1211431 PMID 8740933 Blanco M Hernandez MT Strauss KW Amaya M October 2013 Prevalence and risk factors of lipohypertrophy in insulin injecting patients with diabetes Diabetes amp Metabolism 39 5 445 53 doi 10 1016 j diabet 2013 05 006 PMID 23886784 Retrieved from https en wikipedia org w index php title Lipohypertrophy amp oldid 1187847542, wikipedia, wiki, book, books, library,
